Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Dilution |
1:500-1:3000 |
Not tested in other applications.
Calculated MW
Positive Control
293T , A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji
Form
Liquid
Buffer
0.1M Tris-Glycine (pH7), 10% Glycerol
Preservative
0.01% Thimerosal
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Recombinant protein encompassing a sequence within the C-terminus region of human VEGF Receptor 3. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_1950291
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Synonyms
fms related tyrosine kinase 4 , FLT-4 , FLT41 , LMPH1A , LMPHM1 , PCL , VEGFR-3 , VEGFR3
Cellular Localization
Membrane; Single-pass type I membrane protein
Background
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq]
Database
Research Area